We compare, we don't sell.Some links pay us. How we make money
Peptide Chooser
Compare by goal

Peptides for recovery and joints: what the evidence in people shows.

Peptide Chooser editorial team. Checked 2 Nov 2026.

Short answer

BPC-157 and TB-500, the peptides sold for injuries and joints, are not FDA approved for any use.1 A 2026 review found three small studies of BPC-157 in people, 30 people in all, and rated the evidence very low in certainty.2 For TB-500 the FDA found no data in people.3 The usual treatments for tendon and joint pain are not peptides: rest, ice, exercise, physical therapy, pain relievers and, if needed, injections.45

Which peptides are sold for recovery and joints?

Two, mostly, and our recovery page lists both:

  • BPC-157: Not approved; FDA proposed excluding it from compounding (Jul 2026). The most searched "healing peptide". Animal studies only; the FDA reviewed it for pharmacy compounding on 23 Jul 2026 and proposed keeping it off the list.
  • TB-500: Not approved; FDA proposed excluding it from compounding (Jul 2026). A copy of a natural repair protein, sold alongside BPC-157. Same July 2026 review, same proposal.

Shops sell them as powder in a vial, often side by side. People buy them for torn tendons, sore knees and sports injuries.

Why do people try them?

Because injuries can take a long time to get better, and a vial promises a shortcut. The stories on shop pages and forums are not trial results: none of the three studies in people compared BPC-157 with a placebo or another treatment.2

What is their FDA status?

Neither is FDA approved for any use.1 From our database:

  • BPC-157: not approved: its nomination for pharmacy compounding was withdrawn.3
  • TB-500: not approved: its nomination for pharmacy compounding was withdrawn.3

In July 2026 the FDA's advisory committee on pharmacy compounding reviewed both, and the FDA proposed not to let pharmacies use them.7

What do the studies in people show?

For BPC-157, a 2026 review searched four databases for any study in people. It found three, with 30 people in all:2

  • a look back at 16 patients given BPC-157 shots into the knee for pain;
  • a look back at 12 patients treated for a bladder condition;
  • a safety test in two people.

None had a comparison group. Most people reported feeling better, but the reviewers rated the studies poor and the evidence very low in certainty, and said BPC-157 should be used in people only inside proper clinical trials.2

For TB-500, the FDA says it found no data on its use in people.3 We found no trial in people either. Our guide BPC-157 vs TB-500 puts the two side by side.

What does the FDA say about the risks?

The FDA lists both among substances that may be risky when pharmacies use them to make medicines. Both may set off an immune reaction when given some ways, and for both the FDA says it lacks the information to know whether they would cause harm.3

What is used for tendon and joint pain instead?

None of these is a peptide.

  • Tendinitis: the aim is to reduce pain and swelling. Rest, wrapping or raising the area and medicines can help, ice for recent injuries, and then ultrasound, physical therapy, steroid shots or surgery.4
  • Osteoarthritis: treatment usually starts with exercises for strength and balance, weight loss if needed, and braces or shoe inserts. Pain relievers and creams can be bought without a prescription; a provider may add shots into the joint or prescription pain relievers, and surgery if nothing else helps.5

A doctor or physical therapist can tell you which fits your injury.

What do the peptides cost?

78 shops we track list BPC-157; the middle price across their listings is $5.95 per mg.6 75 shops we track list TB-500; the middle price across their listings is $6.65 per mg.6

The windows on our recovery page list each shop with its five checks; we never link to the shops. A price per mg says nothing about what is in the vial, and a lab report covers one batch: see how to read a COA.

None of this is medical advice.

What to do next

Compare recovery optionsBPC-157 vs TB-500 guide

Sources

  1. Drugs@FDA, searched through openFDA for BPC-157, GHK-Cu (also as copper tripeptide and prezatide) and TB-500 (also as thymosin beta-4): no approved product, 2 Nov 2026: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
  2. Poolton JT et al., Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review, Acta Orthop Belg 92(3), 2026, PubMed 42885452: https://pubmed.ncbi.nlm.nih.gov/42885452/
  3. FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, current as of 22 Apr 2026: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  4. MedlinePlus, Tendinitis: https://medlineplus.gov/tendinitis.html
  5. MedlinePlus, Osteoarthritis: https://medlineplus.gov/osteoarthritis.html
  6. Peptide Chooser database: the research-use and cosmetic peptide shops we check, 2 Nov 2026. Their prices and checks are in the seller windows on our goal pages
  7. FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting, 23 and 24 Jul 2026 (BPC-157, TB-500, MOTS-c, epitalon): https://www.fda.gov/media/193342/download